Adaptive Bio

Moat components and durability. Intangible assets: strong. clonoSEQ is the first and only FDA‑cleared NGS MRD test in MM and B‑ALL bone marrow and in blood/bone marrow for CLL, is in NCCN guidelines and has broad U.S. coverage (over 300 million covered lives), which reinforces brand, clinical trust and reimbursement positioning.

Score 78. Switching costs: medium. Integrations into EMRs (Epic and others) reduce friction for clinicians and embed workflows; as of December 2025 clonoSEQ was integrated into Epic instances at 54 customer sites and by mid‑2026 the company cites over 175 EMR‑integrated accounts.

Score 65. Network effects: moderate in Immune Medicine, limited in MRD. The immune receptor dataset and TCR‑antigen mapping may compound discovery value but is still early for monetization; management cites more than 6 million functional TCR‑antigen pairs and >10,000 patients profiled. Score 50. Cost advantages: moderate.

Centralized lab scale, rising volumes, and improving reimbursement lift gross margins into the 70%+ range; however, competitors can run LDTs and incumbents in flow cytometry remain. Score 55. Efficient scale: moderate.

Hematology MRD is a focused market with high fixed validation and clinical evidence requirements that deter fast me‑too entrants, but LDTs remain viable after the 2025 court outcome.

Score 55. Global view: weighted average about 62; moat is real in MRD but not yet indestructible, and durability hinges on maintaining clinical guideline leadership, real‑world evidence and payer support.

Evidence of pricing power exists but is not absolute. The 2025 publication of a 2,007 dollar Medicare CLFS price for clonoSEQ and expanded coverage in DLBCL and MCL point to improving ASP and reimbursement durability. Score uplift.

Counterweights include the persistence of LDT competitors following the vacatur and rescission of FDA’s LDT rule and alternative modalities such as flow cytometry, which cap latent pricing.

Given MRD’s strong clinical utility and low test share of total cancer‑care economics, some future pricing room likely remains as evidence broadens, but we conservatively view pricing power as moderate rather than dominant.

Revenue visibility is improving but not yet at tollbooth levels. TTM revenue is roughly 295 million dollars (2025 total 276.98 plus Q1 2026 70.87 minus Q1 2025 52.44), with Q1 2026 MRD revenue up 53% year over year and full‑year 2026 MRD guidance raised to 260–270 million dollars.

This reflects a healthy recurring‑testing dynamic as patients are monitored longitudinally. However, consolidated earnings and cash flows remain negative, and Immune Medicine revenue is lumpy after the termination of the Genentech collaboration effective February 2026. The Microsoft collaboration has also concluded, reducing non‑MRD visibility.

Geographic and payer concentration are U.S.‑heavy but in a favorable jurisdiction. On balance, we assign mid‑50s for predictability.

Liquidity and structure improved in mid‑2026. As of March 31, 2026, cash, cash equivalents and marketable securities were 237.2 million dollars (including Digital Biotechnologies cash in the press release figure), and TTM operating cash burn had narrowed.

In June 2026 the company issued 0% convertible notes due 2031 and used proceeds to repay the OrbiMed revenue interest obligation for 156.9 million dollars, fund capped calls and repurchase shares, effectively removing a 5% of revenue royalty‑like drag and interest expense.

Pro forma, net cash is roughly neutral given cash on hand and the new convert. Offsets: TTM FCF is still about negative 30 million dollars (TTM CFO around negative 27 million dollars plus about 2.5 million dollars capex), and stock‑based compensation remains significant (51.5 million dollars in 2025).

Overall balance sheet risk is moderate with improved flexibility after the refinancing.

Recent decisions align with quality discipline: focusing on MRD, segment reporting, and now pursuing a separation of Immune Medicine to unlock value clarity. The June 2026 refinancing retired the costly OrbiMed revenue interest, added capped calls to mitigate dilution, and included a small share repurchase.

On the negative side, stock‑based compensation remains elevated relative to revenue, and share count rose to about 160 million outstanding by March 31, 2026. We score management’s capital allocation above average given the removal of a structurally expensive liability and focus on the highest‑return MRD opportunities, while noting the need to curb dilution.

Founder‑led team with deep domain expertise. CEO and cofounder Chad Robins and CSO and cofounder Harlan Robins remain in place, and Kyle Piskel has served as CFO since 2024, steering a more disciplined operating approach. Communication of strategy and segment metrics has improved.

Execution in MRD has been strong, though the Immune Medicine path has changed (Genentech termination, Microsoft collaboration concluded), and operating leverage needs to translate into sustained positive FCF to validate long‑term stewardship quality.